Novo Nordisk to create 6000 jobs by 2022


Danish insulin and diabetes specialist Novo Nordisk says it intends to employ 6000 more highly skilled workers within Denmark by 2022. Half of these new staff will work in R&D. The announcement bucks the trend of recent years in pharma, which has tended to see companies downsizing drastically and closing R&D sites.

The company used its announcement to call on the Danish government to prioritise investment in research-based training in the sciences to ensure that research-driven Danish companies can continue to grow. ‘It will be crucial for Novo Nordisk that Denmark educates world-class graduates but also focuses far more intently on attracting international talent,’ said the firm’s chief science officer, Mads Krogsgaard Thomsen in a statement.


Related Content

Novo Nordisk quits inflammation R&D and cuts jobs

3 September 2014 Business

news image

Firm will return to primary focus on diabetes and obesity

$100m of diabetes R&D in China

24 September 2012 Business

news image

Novo Nordisk will create 130–200 new research jobs

Most Read

First pictures of hydrogen bonds unveiled

26 September 2013 Research

news image

Observation of intermolecular interactions in quinolines could help to settle the nature of this kind of bonding

Copper catalysis overcomes double bond trouble

3 July 2015 Research

news image

Stubbornly stable unactivated internal alkenes become chiral tertiary amine precursors

Most Commented

Collaboration, not competition

29 June 2015 Research

news image

Organic chemist E J Corey talks to Phillip Broadwith about awards, ambition and academic freedom

Z machine puts the squeeze on metallic deuterium

25 June 2015 Research

news image

Pressures similar to those at centre of the Earth forge metallic deuterium in step toward 80-year-old dream of creating metal...